ArisGlobal’s 2025 Surge Signals AI Has Arrived in Life Sciences

BOSTON, MA – January 13, 2026 – The life sciences industry has reached a critical inflection point in its adoption of artificial intelligence, moving the technology from isolated pilot programs to enterprise-wide operational reality. This shift is underscored by a landmark year for ArisGlobal, an AI-first technology company, which reported unprecedented growth and accelerated adoption of its AI-powered LifeSphere® platform in 2025. The company's performance, marked by major customer acquisitions and successful large-scale deployments, suggests that the long-promised era of AI-driven efficiency and innovation in drug development is finally taking hold.

Throughout 2025, the Boston-based firm helped pharmaceutical and biotech organizations modernize core functions in Safety, Regulatory, and R&D, tackling mounting data volumes and regulatory complexity. The results signal a clear market trend: AI is no longer a theoretical advantage but a core component of the modern life sciences operating model.

The Tipping Point: From Experiment to Enterprise Scale

For years, the narrative around AI in pharmaceuticals has been one of potential. ArisGlobal's 2025 results provide concrete evidence that this potential is now being realized at scale. The company announced it had secured over 100 combined net new customers and significant expansions with existing clients. Most notably, adoption of its NavaX AI capabilities surged, with a 125% year-over-year increase in customers for the AI engine, primarily in the critical domains of drug safety and regulatory affairs.

This growth isn't limited to smaller, agile biotechs. The company successfully completed 38 global go-live implementations, including complex programs for three of the world's top 10 pharmaceutical giants. These deployments span 22 safety systems, 11 regulatory platforms, and 5 enterprise-level NavaX implementations, reinforcing the technology's readiness for the industry's most demanding environments.

"Customers are no longer experimenting with AI – they're operationalizing it," said Steve Nuckols, Chief Customer Officer at ArisGlobal. "What we're seeing is clear momentum: larger deployments, faster expansions, and a growing focus on results like cycle time reduction, consistency, and inspection readiness."

This momentum is fueled by tangible outcomes. For instance, Boehringer Ingelheim, a major pharmaceutical partner, reported achieving 90% data accuracy within weeks of implementing NavaX for safety case intake, dramatically reducing manual effort. Another top 10 global pharma client noted meaningful efficiency gains and strong data accuracy shortly after deploying the AI solution across its global safety processes. This increasing confidence is reflected in the 31% of existing LifeSphere customers who expanded their use of the platform in the first half of 2025 alone.

Orchestrating a New Era of R&D Innovation

ArisGlobal's success is rooted in a strategic shift from offering isolated AI features to providing an interconnected, intelligence-driven ecosystem. The company's 2025 product launches focused on what it calls "intelligent orchestration," aiming to break down the data silos that have long hindered cross-functional collaboration in life sciences.

A key innovation is Unify, a data orchestration layer connecting previously disparate information from Safety, Regulatory, Quality, and Medical Affairs. By creating a shared data foundation, Unify provides a single source of truth that enables comprehensive visibility, streamlined reporting, and more informed decision-making across the entire product lifecycle.

Building on this connected data, the company introduced NavaX Agents, a new form of agentic AI designed to automate complex cognitive tasks. The first of these, the MedDRA Coding Agent, transforms the critical but labor-intensive process of coding adverse event terms. This agent, which earned ArisGlobal the prestigious Frost & Sullivan 2025 New Product Innovation Award, emulates human-level judgment to deliver consistent and compliant medical coding, significantly reducing manual review burdens. It represents a leap from simple automation to autonomous intelligence that can reason and collaborate within the LifeSphere platform.

"2025 marked a turning point where AI stopped being theoretical and started delivering results," noted Ann-Marie Orange, CIO and Global Head of R&D. "With NavaX and Unify, customers aren't just automating tasks – they're orchestrating data and decisions across the enterprise."

The operational impact of this technology is substantial. Today, NavaX processes a collective 700,000 cases annually for its customers. With the current trajectory of adoption, ArisGlobal projects that number will expand to an astounding 2.5 million cases by mid-2026.

Redefining Compliance and Safety with Intelligent Automation

In the highly regulated pharmaceutical landscape, innovation must go hand-in-hand with unwavering compliance. ArisGlobal's AI-first solutions are designed not only to boost efficiency but also to enhance regulatory adherence and patient safety. As global health authorities impose stricter requirements and adverse event data grows exponentially, traditional manual processes are becoming unsustainable.

AI-powered automation helps organizations manage this complexity with greater speed and accuracy. By automating routine tasks in pharmacovigilance and regulatory submissions, teams can focus on higher-value strategic activities, risk analysis, and signal detection. The ability to process vast datasets consistently reduces the risk of human error and strengthens a company's inspection readiness.

"Our teams operate with the same sense of urgency our customers live with every day," said Raj Hattarki, Chief Operating Officer. He emphasized that even with complex global programs, the focus remains on helping customers go live faster without compromising the compliance foundation essential for long-term success. "With NavaX in particular, our focus has been unwavering: accelerating time to value. Every day saved matters, because every day lost is a missed opportunity to create impact for our customers."

A Commitment to Trust in a Regulated World

As AI becomes more powerful and autonomous, the importance of ethics and responsibility grows, particularly in a field with direct impact on human health. Recognizing this, ArisGlobal has taken a proactive stance on responsible AI development. In February 2025, the company became a signatory of the EU AI Pact, a voluntary initiative by the European Commission to prepare organizations for the forthcoming EU AI Act, the world's first comprehensive law on artificial intelligence.

By joining the pact, ArisGlobal publicly committed to upholding best practices in AI governance and ethics. This includes developing a robust internal AI governance strategy, mapping systems that may be classified as high-risk, and promoting AI literacy across its organization. This commitment to "trust by design" is a crucial pillar of the company's strategy, aiming to build confidence among customers and regulators alike as AI's role in the industry deepens.

Building on its 2025 momentum, ArisGlobal enters the new year with a clear vision for the future of life sciences technology. "This year proved what's possible when AI is deployed responsibly and designed for real-world operations," stated CEO Aman Wasan. "As AI enters its enterprise phase, our focus is clear: intelligent orchestration, trust by design, and outcomes that matter for patients, regulators, and teams who support them."